For the quarter ending 2025-06-30, YMAB had -$4,941K decrease in cash & cash equivalents over the period. -$5,387K in free cash flow.
| Cash Flow | 2025-06-30 |
|---|---|
| Inventories, long-term | 1,451 |
| Inventories | 2,394 |
| Accrued liabilities and other | -4,376 |
| Stock-based compensation | 6,243 |
| Net loss | -8,436 |
| Other assets | 158 |
| Other current assets | -338 |
| Accounts receivable, net | -3,948 |
| Accounts payable | 3,654 |
| Foreign currency transactions | 2,752 |
| Depreciation and amortization | 124 |
| Net cash used in operating activities | -5,260 |
| Purchase of property and equipment | 127 |
| Net cash used in investing activities | -127 |
| Proceeds from exercised stock options | 446 |
| Net cash provided by financing activities | 446 |
| Net decrease in cash and cash equivalents | -4,941 |
Y-mAbs Therapeutics, Inc. (YMAB)
Y-mAbs Therapeutics, Inc. (YMAB)